{
  "docId": "019de071-732e-725a-82b2-fadda5c9262b",
  "docSlug": "53608d8491e21d9b182fee59cb598fc5",
  "documentTitle": "AbCellera | Investor Conference Presentation Deck | 18 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 18,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide highlights clinical impact and variant efficacy for two specific antibody therapies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-732e-725a-82b2-fadda5c9262b/17",
  "deckHref": "/decks/019de071-732e-725a-82b2-fadda5c9262b",
  "deckJsonHref": "/decks/019de071-732e-725a-82b2-fadda5c9262b.json",
  "deckAnchorHref": "/decks/019de071-732e-725a-82b2-fadda5c9262b#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.512,
        "y": 0.125
      },
      "kind": "callout",
      "text": "bamlanivimab + etesevimab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c555042-ec74-4379-bbf0-f7990cd3e51c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.512,
        "y": 0.54
      },
      "kind": "callout",
      "text": "bebtelovimab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f434011-34b8-4b07-b4ad-d9e5e414a1c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.512,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Bamlanivimab alone and together with etesevimab has been used to treat more than 535,000 patients, potentially preventing 20,000+ hospitalizations and 10,000 deaths.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ebeb6fd-9064-48ed-8d23-166351c03c3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.435,
        "x": 0.08,
        "y": 0.615
      },
      "kind": "paragraph",
      "text": "There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3a36cd3-27a4-4a16-887f-e7983574ff47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.512,
        "y": 0.66
      },
      "kind": "paragraph",
      "text": "Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca3e59ac-c758-494f-afca-b65a9bfa9bd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.615,
        "y": 0.935
      },
      "kind": "source-note",
      "text": "* Shown to be effective against the Delta variant in preclinical studies",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a95ef5ca-73fc-4cc3-b54c-d55638e047e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.435,
        "x": 0.08,
        "y": 0.135
      },
      "kind": "title",
      "text": "2 ANTIBODIES FOR COVID-19",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d78f5cc-c80f-4351-8a36-c2ddd10537ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 6,
      "beatId": "090a5d0f-097a-4e7d-b542-08dd2594c5ea",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Unlock the natural antibody database to find new treatments with modern technologies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6758412a-38f7-42b9-9bf8-b71e868d7568",
      "evidence": "The deck outlines the vision, approach, and benefits of AbCellera's technology",
      "position": 1,
      "objective": "Explain the why, what, and how of AbCellera's approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}